messag view mrk in-lin outlook beli strength
busi sustain keytruda growth remain cornerston driven penetr
intenational market new indic commentari upcom kidney cancer
combo abstract full data suggest excel result impact clinic
practic ceo ken frazier state mrk pipelin broadest
mani year therapeut categori agnost bd strategi non-disrupt
remain one top pick increas pt
growth opportun ahead keytruda approv new indic
wake strong quarter keytruda beat consensu
forecast management expect growth increas market penetr approv
indic global addit near-term approv
growth current label increment penetr
us market expect see uptak recent label expans
squamou nsclc combin taxane-bas regimen follow
approv studi use expand neg
popul non-squam nsclc keytruda chemo combo although
keytruda came later newli approv indic like adjuv melanoma
confid data convinc keytruda becom market leader
compani cite prior experi bladder cancer keytruda fifth
launch io agent us indic lead share driven
overal surviv benefit
ex-u market start roll keytruda still earli
commerci exampl keytruda approv one indic
melanoma china last year given approv keytruda anticip
intern market management see signific growth potenti ahead particularli
eu japan china
expect label expans watch data gu abstract
full present
call management enthusiasm potenti uptak renal cell carcinoma
rcc data palpabl trial stop first
interim efficaci evalu deliv posit benefit os overal respons
rate across risk group see present entir data
asco-gu feb view data convinc physician make
keytruda top treatment choic rcc patient postur impli futur
potenti challeng neutral whose opdivo current io leader
rcc
management also excit neoadjuv studi tripl neg breast cancer
tnbc trial note earli data share regulatori
agenc agre wait long-term follow-up result management express
confid result like would posit believ
earli dataset like strong support potenti approv howev given
complic trial design four cycl treatment pre-surgeri nine cycl
treatment surgeri believ confirm long-term benefit like
page analyst certif import disclosur
market drug like gardasil lynparza grow strongli besid
keytruda also see growth potenti key drug across portfolio
gardasil although sale somewhat estimate
consensu still strong uptak china eu gender-neutr
vaccin program sustain growth management believ vaccin still
signific growth ahead system around world aim reduc incid
certain hpv-relat cancer earlier expect approv see
lynparza secur lead posit parp inhibitor market
patient share furthermor expect see larger commerci opportun
previous thought evid accumul show even cell type without
recogniz dna repair defect cell still respons lynparza suggest broader
spectrum activ co-develop azn buy collabor esali
lenvima tyrosin kinas inhibitor also show good market perform
hepatocellular cancer follow launch europ recent china
current domin tumor market japan on-going clinic trial evalu lenvima
combin keytruda multipl cancer type expand overal lenvima
one promis pipelin decad interest mega deal
would disrupt progress management proud diversifi high potenti
pipelin includ drug candid uniqu mechan action moa
oncolog next-gener vaccin pneumococc diseas rsv cmv dengu
management continu highlight nucleosid revers transcriptas transloc
inhibitor nrtti novel moa current test ph trial combin
doravirin believ molecul remark efficaci durabl could potenti
disrupt hiv treatment landscap detail mrk pipelin asset discuss
 investor event schedul june besid intern develop
busi develop execut transact span licens deals/
clinic collabor well acquisit viralyt antelliq howev management
reiter call compani limit focu potenti deal minim risk
disrupt on-going process interest mega
deliv leverag despit expect invest growth support
develop keytruda lynparza key drug expect increas
invest next sever year rate higher sale growth despit management
forecast oper margin expans partial due anticip tight control
sg compani forese long-term margin expans particularli spend
slow coupl year
ceo frazier welcom hh propos restructur rebat system patient
regard recent hh propos elimin safe harbor protect drug rebat
welcom propos find direct construct lower out-of-
pocket cost patient echo novo comment earn call
compani evalu detail polici propos hope achiev share
goal restructur current rebat system pass save patient
page analyst certif import disclosur
valuat risk
valu result estim chang valuat
base dcf analysi assum wacc line larg cap pharma
peer termin growth rate
downsid risk includ deceler gardasil growth neg keytruda readout
next month chang price environ oncolog drug
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
